| A recombinant human monoclonal antibody being developed by Celltrion Inc. for the treatment of coronavirus disease 2019 (COVID-19). |
| Received its first approval on 17 September 2021 in South Korea. |
| Approved for use in COVID-19. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.